A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
PHASE2CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
May 12, 2018
Primary Completion Date
September 1, 2020
Study Completion Date
September 1, 2020
Conditions
Hepatitis C
Interventions
DRUG
Mavyret
Patients will be on 8 weeks of Mavyret
Trial Locations (1)
10016
New York University School of Medicine, New York
All Listed Sponsors
lead
NYU Langone Health
OTHER
NCT03523871 - A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret | Biotech Hunter | Biotech Hunter